Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia

Journal of Perinatal Medicine

Volumn 40, Issue 4, 2012, Pages 397-402

  Pfenniger, Anita ^a   Schuller, Christine ^a   Christoph, Patricia ^a   Surbek, Daniel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Ferinject ; Hemoglobin; Iron carboxymaltose; Iron sucrose; Parenteral iron substitution; Venofer postpartum anemia

Indexed keywords

FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON SACCHARATE;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE; BLOOD TRANSFUSION; COHORT ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HELLP SYNDROME; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; INJECTION SITE BURNING; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTPARTUM ANEMIA; PREECLAMPSIA; PRIORITY JOURNAL; PUERPERIUM; RETROSPECTIVE STUDY; SHIVERING; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; BLOOD TRANSFUSION; COHORT STUDIES; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; MALTOSE; PUERPERAL DISORDERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84869424514     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2011-0239     Document Type: Article

References (35)

1. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008;83: 580-8. (Pubitemid 351874877)
2. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung. 2010;60: 386-98.
3. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron defi- ciency anemia. Hemodial Int. 2010;14: 47-54.
4. Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: review of the literature. Eur J Obstet Gynecol Reprod Biol. 2003;110: 2-7. (Pubitemid 37025688)
5. Beard JL, Hendricks MK, Perez EM, Murray-Kolb LE, Berg A, Vernon-Feagans L, et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. J Nutr. 2005;135: 267-72. (Pubitemid 40194489)
6. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. Br J Obstet Gynaecol. 2006;113: 1248-52. (Pubitemid 44581513)
7. Bodnar LM, Scanlon KS, Freedman DS, Siega-Riz AM, Cogswell ME. High prevalence of postpartum anemia among low-income women in the United States. Am J Obstet Gynecol. 2001;185: 438-43. (Pubitemid 32769448)
8. Bodnar LM, Cogswell ME, Scanlon KS. Low income postpartum women are at risk of iron deficiency. J Nutr. 2002;132: 2298-302. (Pubitemid 34851665)
9. Bodnar LM, Cogswell ME, McDonald T. Have we forgotten the significance of postpartum iron deficiency? Am J Obstet Gynecol. 2005;193: 36-44. (Pubitemid 41001325)
10. Breymann C. Iron deficiency and anemia in pregnancy: modern aspects of diagnosis and therapy. Eur J Obstet Gynecol Reprod Biol. 2005;123: 3-11.
11. Breymann C, Richter R. Effectiveness of rhEPO and iron sucrose vs iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest. 2000;30: 154-61. (Pubitemid 30079574)
12. Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenous iron sucrose with and without rhEPO for resistant iron deficiency anemia in pregnancy. Am J Obstet Gynecol. 2000;184: 662-7.
13. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet. 2008;101: 67-73.
14. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010;282: 577-80.
15. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25: 2722-30.
16. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60: 345-53.
17. Geisser P. Pharmakologie und Sicherheitsprofil von Eisen- Carboxymaltose (Ferinject p): Struktur/Reaktivitäts-Verhältnisse von Eisenpräparaten. Port J Nephrol Hypert. 2009;23: 11-6.
18. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60: 362-72.
19. Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60: 373-85.
20. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;20;5: 51-60.
21. Huch R, Breymann C. Anämie in Schwangerschaft und Wochenbett. 1. Auflage. Bremen: UNI-MED Verlag AG; 2005.
22. Kersten D, Surbek D. Eisenmangelanämie in der Geburtshilfe. Bedeutung, Differenzialdiagnostik und Therapiemöglichkeiten. Gynäkologie. 2008;3: 27-9.
23. Kociol RD, Newby LK. Ferric carboxymaltose improved symptoms and quality of life in patients with chronic heart failure and iron deficiency. Ann Intern Med. 2010;20;152:JC4-5.
24. Lyseng-Williamson KA, Keatin GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69: 739-56.
25. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009;12: 444-54.
26. Milmann N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91: 143-54.
27. Perewusnyk G, Huch R, Huch A, Breymann C. Parenteral iron therapy in obstetrics: 8 years experience with iron sucrose complex. Br J Nutrit. 2002;88: 3-10. (Pubitemid 34752309)
28. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010;60: 399-412.
29. Schaefer RM, Khasabov NN. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia (abstract no. MP375 plus poster). 45th Congress of the European Renal Association and the European Dialysis and Transplant Association, Stockholm. 2008.
30. Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia. Blood. 2006;108:abstract 3739.
31. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of post partum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199: 4351-7.
32. Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, et al. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010;25: 2368-75.
33. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant. 2010;25: 3631-40.
34. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jahle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49: 2719-28.
35. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1): 267-78. (Pubitemid 47356650)